Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.

Martner, Anna ; Rydström, Anna ; Riise, Rebecca E ; Aurelius, Johan ; Anderson, Harald LU ; Brune, Mats ; Foà, Robin ; Hellstrand, Kristoffer and Thorén, Fredrik B (2015) In OncoImmunology 5(1). p.1041701-1041701
Abstract
In a phase IV trial, 84 patients (age 18-79) with acute myeloid leukemia (AML) in first complete remission (CR) received cycles of immunotherapy with histamine dihydrochloride (HDC) and low-dose human recombinant interleukin 2 (IL-2) for 18 months to prevent leukemic relapse. During cycles, the treatment resulted in expansion of CD56(bright) (CD3(-)/16(-)/56(bright)) and CD16(+) (CD3(-)/16(+)/56(+)) natural killer (NK) cells in the blood along with increased NK cell expression of the natural cytotoxicity receptors (NCRs) NKp30 and NKp46. Multivariate analyses correcting for age and risk group demonstrated that high CD56(bright) NK cell counts and high expression of NKp30 or NKp46 on CD16(+) NK cells independently predicted leukemia-free... (More)
In a phase IV trial, 84 patients (age 18-79) with acute myeloid leukemia (AML) in first complete remission (CR) received cycles of immunotherapy with histamine dihydrochloride (HDC) and low-dose human recombinant interleukin 2 (IL-2) for 18 months to prevent leukemic relapse. During cycles, the treatment resulted in expansion of CD56(bright) (CD3(-)/16(-)/56(bright)) and CD16(+) (CD3(-)/16(+)/56(+)) natural killer (NK) cells in the blood along with increased NK cell expression of the natural cytotoxicity receptors (NCRs) NKp30 and NKp46. Multivariate analyses correcting for age and risk group demonstrated that high CD56(bright) NK cell counts and high expression of NKp30 or NKp46 on CD16(+) NK cells independently predicted leukemia-free survival (LFS) and overall survival (OS). Our results suggest that the dynamics of NK cell subsets and their NCR expression may determine the efficiency of relapse-preventive immunotherapy in AML. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
OncoImmunology
volume
5
issue
1
pages
1041701 - 1041701
publisher
Landes Bioscience
external identifiers
  • pmid:26942055
  • wos:000373383600040
  • pmid:26942055
  • scopus:84954431921
ISSN
2162-4011
DOI
10.1080/2162402X.2015.1041701
language
English
LU publication?
yes
id
074da494-bc05-428e-9891-35ccef68c78f (old id 8856243)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26942055?dopt=Abstract
date added to LUP
2016-04-01 10:27:31
date last changed
2022-02-17 18:13:20
@article{074da494-bc05-428e-9891-35ccef68c78f,
  abstract     = {{In a phase IV trial, 84 patients (age 18-79) with acute myeloid leukemia (AML) in first complete remission (CR) received cycles of immunotherapy with histamine dihydrochloride (HDC) and low-dose human recombinant interleukin 2 (IL-2) for 18 months to prevent leukemic relapse. During cycles, the treatment resulted in expansion of CD56(bright) (CD3(-)/16(-)/56(bright)) and CD16(+) (CD3(-)/16(+)/56(+)) natural killer (NK) cells in the blood along with increased NK cell expression of the natural cytotoxicity receptors (NCRs) NKp30 and NKp46. Multivariate analyses correcting for age and risk group demonstrated that high CD56(bright) NK cell counts and high expression of NKp30 or NKp46 on CD16(+) NK cells independently predicted leukemia-free survival (LFS) and overall survival (OS). Our results suggest that the dynamics of NK cell subsets and their NCR expression may determine the efficiency of relapse-preventive immunotherapy in AML.}},
  author       = {{Martner, Anna and Rydström, Anna and Riise, Rebecca E and Aurelius, Johan and Anderson, Harald and Brune, Mats and Foà, Robin and Hellstrand, Kristoffer and Thorén, Fredrik B}},
  issn         = {{2162-4011}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{1041701--1041701}},
  publisher    = {{Landes Bioscience}},
  series       = {{OncoImmunology}},
  title        = {{Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.}},
  url          = {{http://dx.doi.org/10.1080/2162402X.2015.1041701}},
  doi          = {{10.1080/2162402X.2015.1041701}},
  volume       = {{5}},
  year         = {{2015}},
}